IXIARO: Valneva’s flagship Japanese encephalitis travel vaccine in focus

Valneva’s IXIARO vaccine targets Japanese encephalitis risk for travelers and military personnel, with FDA approval, defined dosing, and broad U.S. availability through travel clinics and major distributors.

Responsible: ad hoc news Classics & Long-sellers Desk. Reviewed prior to publication on June 14, 2026 at 4:06 PM ET. Details in the imprint.

IXIARO is Valneva's inactivated Japanese encephalitis vaccine and one of the company's most established travel vaccines for people visiting endemic regions in Asia and parts of the Western Pacific. The product has been licensed in the United States for more than a decade and remains the only Japanese encephalitis vaccine approved by the U.S. Food and Drug Administration (FDA) for use in adults and children as young as 2 months. IXIARO is indicated for travelers, expatriates, and military personnel who expect potential exposure through outdoor activities, rural stays, or long-term residence in areas where Japanese encephalitis virus circulates. As a core part of Valneva's travel vaccine franchise, IXIARO continues to generate recurring revenues even as the company shifts strategic focus toward its Lyme disease and chikungunya programs.

What IXIARO does and who it is for

IXIARO is a purified, inactivated Japanese encephalitis vaccine based on the SA14-14-2 strain of the virus, produced in Vero cells and formulated with aluminum hydroxide as an adjuvant. Japanese encephalitis is a mosquito-borne viral infection that can cause severe inflammation of the brain, with case fatality rates reported up to 30 percent and long-term neurologic sequelae in many survivors. While the overall risk for short-term travelers is low, those spending extended time in rural or agricultural areas, especially during transmission season, can face higher exposure risk, which is why vaccines like IXIARO are recommended in CDC and WHO travel guidelines for certain itineraries. The vaccine is not intended for general population use but rather for individuals whose travel or deployment patterns bring them into environments where the virus is present in pigs, wading birds, and mosquito vectors.

For adults and children 3 years of age and older, the approved IXIARO schedule consists of two intramuscular doses of 0.5 mL each, typically administered on day 0 and day 28, with the series needing to be completed at least one week before potential exposure. In the U.S. product label, children aged 2 months through 2 years receive a smaller 0.25 mL dose on the same dosing days. Clinical studies submitted to regulators showed that more than 95 percent of vaccine recipients achieved protective neutralizing antibody titers after completion of the primary series, and subsequent booster studies indicated that immunity can be extended with a third dose for people who remain at ongoing risk, such as residents or repeat travelers to endemic regions. As always with vaccines, healthcare providers are advised to weigh individual risk factors, contraindications, and medical history when deciding on immunization.

In the United States, IXIARO holds an FDA Biologics License for use in individuals aged 2 months and older and is distributed in single-dose vials that must be stored and transported in the cold chain at 2 to 8 degrees Celsius. Valneva's commercial strategy has focused on travel medicine clinics, specialized vaccination centers, and government or military procurement channels, rather than mass retail pharmacies, which reflects the targeted nature of the indication. That said, U.S. travelers can typically access the vaccine through dedicated travel clinics associated with major hospital systems, university health centers, and private practices that maintain travel vaccine inventories, often with prior scheduling because of the multi-dose regimen and cold-chain planning. Commercial distribution in the U.S. has also involved partnerships with wholesalers and government agencies, particularly the U.S. military, which uses Japanese encephalitis vaccination for personnel deployed to certain bases in Asia.

Outside the United States, the same vaccine is marketed under the JEVAC or JESPECT brand names in some markets, but the IXIARO label is the one most relevant for U.S. consumers and investors following Valneva's travel vaccine business. Regulatory approvals have been obtained in the European Union, Australia, and several other countries, and public health recommendations in those jurisdictions similarly position the vaccine for travelers or residents with defined exposure risks rather than for universal immunization. For U.S.-based travelers, the main practical questions tend to be where to get vaccinated, how long before departure to start the series, and what insurance coverage looks like, since travel vaccines are often reimbursed differently from routine childhood immunizations. Valneva emphasizes in its materials and investor presentations that Japanese encephalitis vaccination remains a niche but steady market, tied to global mobility patterns, tourism flows, and military deployments.

From a pricing perspective, public sources and travel clinic fee schedules indicate that IXIARO is typically billed in the United States at a per-dose price in the range that is common for specialized travel vaccines, often translating into several hundred U.S. dollars for the full two-dose series including clinic administration fees, though exact out-of-pocket costs vary by provider and insurance coverage. Because list prices and clinic charges can change with negotiations, distributor contracts, and health-system policies, Valneva does not publicly quote a fixed U.S. retail price across its communications, and travelers are generally advised to confirm current costs directly with their chosen clinic. The company has previously disclosed in financial reports that travel vaccines, including IXIARO and its cholera/ETEC vaccine Dukoral, historically contributed a significant share of its product sales, but revenue visibility can be influenced by macro factors such as pandemic-era travel restrictions or shifts in tourism demand. Recent commentary around Valneva's guidance cuts has mentioned weaker demand for travel vaccines as one factor affecting revenues, which underscores how products like IXIARO remain sensitive to global travel dynamics even when their clinical utility is unchanged.

For U.S. consumers planning trips to countries where Japanese encephalitis circulates, IXIARO is usually accessed through pre-travel consultations that also cover malaria prevention, routine vaccine updates, and other destination-specific risks. Providers may use CDC and WHO maps, seasonal data, and itinerary specifics to determine whether Japanese encephalitis vaccination is appropriate, balancing potential exposure against the limited time many travelers spend in rural agricultural areas where the virus is most common. Because the vaccine requires two doses several weeks apart, travelers who book last-minute trips may find it difficult to complete the full series in time; in those cases, clinicians may discuss partial protection, schedule adjustments within label allowances, or emphasize alternative protective measures such as insect repellent, long-sleeved clothing, and bed nets. This interaction between logistics, risk assessment, and traveler behavior helps explain why the Japanese encephalitis vaccine market is stable but not rapidly expanding, even as international tourism resumes after global disruptions.

Against this backdrop, IXIARO represents a mature but strategically important asset in Valneva's portfolio, providing recurring though cyclical revenue while the company advances newer vaccine candidates for Lyme disease and chikungunya in partnership with larger pharmaceutical players. Management commentary around restructuring and cost-saving measures has highlighted travel vaccines as a continuing pillar of the business, even as guidance was reduced amid softer demand. Shares of Valneva SE (FR0013280286, ticker VALN) last traded on Euronext Paris; the company does not currently maintain a primary U.S. listing.

IXIARO at a glance

• Product: IXIARO (Japanese encephalitis vaccine)
• Manufacturer: Valneva SE
• Category: Classic long-term travel vaccine
• Launch date: Initial approvals from 2009 onward in major markets
• MSRP / Price: Typical U.S. clinic pricing totals several hundred US dollars for the two-dose series including administration; exact amounts vary by provider and insurance (as of publicly available fee schedules in 2025)
• Availability: Travel medicine clinics, selected hospital and university health centers, government and military vaccination programs, and specialized vaccine providers in the U.S. and other approved markets
• Target audience: Travelers, expatriates, and military personnel aged 2 months and older with potential exposure to Japanese encephalitis virus in endemic regions
• Key feature / USP: Only FDA-licensed Japanese encephalitis vaccine for use in the U.S. in individuals 2 months of age and older, with a two-dose primary series and established safety and immunogenicity profile

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.